|Day Low/High||629.00 / 655.93|
|52 Wk Low/High||271.37 / 653.53|
Biotech name has bolted higher with some amazing relative strength.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
But don't throw up your arms yet -- here are names that could be golden opportunities.
The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.
Are the technical and quantitative approaches on the same page?
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
RMPIA is up 20.9% in the first nine months of 2019.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
These bearish bets are showing both technical and quantitative deterioration.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
RMPIA outperformed once gain during April.
Netflix is bullish, but faces key resistance before it can make a big run higher.
A low-risk countertrend options trade may be worth a look in this name.
In this day and age, companies must be 'disruptors' or get left in the dust.
So far 2019 is proving to be a year where things have a habit of working out right.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
An updated strategy for the high-flying REGN.
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
We have more evidence to support the bull case.
Stock still needs a period of base building to support advance.